Strs Ohio Seagen Inc. Transaction History

Strs Ohio

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 26, 2023	BUY	$191.51 - $216.16 $2.22 Million - $2.5 Million	11,566 Added 68.04%	28,566 $6.06 Million
Q2 2023 Jul 31, 2023	BUY	$187.64 - $206.25 $1.31 Million - $1.44 Million	7,000 Added 70.0%	17,000 $3.27 Million
Q1 2023 Aug 02, 2023	SELL	$127.59 - $203.08 $893,130 - $1.42 Million	-7,000 Reduced 41.18%	10,000 $2.02 Million
Q1 2023 Apr 27, 2023	BUY	$127.59 - $203.08 $1.28 Million - $2.03 Million	10,000 New	10,000 $2.02 Million
Q2 2022 Jul 25, 2022	SELL	$108.81 - $179.33 $696,275 - $1.15 Million	-6,399 Closed	0 $0

Q1 2022 Apr 21, 2022	SELL	$119.61 - $157.85 $2.86 Million - $3.77 Million	-23,897 Reduced 78.88%	6,399 $921,000
Q4 2021 Jan 24, 2022	SELL	$142.57 - $190.86 $14,684 - $19,658	-103 Reduced 0.34%	30,296 $4.68 Million
Q3 2021 Oct 22, 2021	SELL	$142.45 - $169.82 $186,894 - $222,803	-1,312 Reduced 4.14%	30,399 $5.16 Million
Q2 2021 Jul 26, 2021	SELL	$135.08 - $161.1 $5.28 Million - $6.29 Million	-39,054 Reduced 55.19%	31,711 $5.01 Million
Q1 2021 Apr 23, 2021	BUY	$137.51 - $190.8 $2.99 Million - $4.15 Million	21,741 Added 44.35%	70,765 $9.83 Million
Q4 2020 Jan 25, 2021	BUY	$164.63 - $211.93 $8.07 Million - $10.4 Million	49,024 New	49,024 $8.59 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.